Latest News of NBIX
Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History
By Yahoo! Finance |
2 months ago
Neurocrine Biosciences disappoints investors with Phase 2 data on schizophrenia treatment. The study showed an 18.2-point reduction in symptoms with NBI-1117568 compared to 10.8 points with placebo, a...
Insider Sale: Director William Rastetter Sells 14,250 Shares of Neurocrine Biosciences Inc (NBIX)
By Yahoo! Finance |
3 months ago
On August 15, 2024, Director William Rastetter sold 14,250 shares of Neurocrine Biosciences Inc, owning 37,491 shares now. The company focuses on treatments for neurological and endocrine-related dise...
Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance |
4 months ago
Neurocrine Biosciences and Diurnal Ltd. showcased their neuroendocrinology pipeline at ENDO 2024, featuring primary data from Phase 3 studies of crinecerfont for congenital adrenal hyperplasia. Result...
-
Those who invested in Neurocrine Biosciences (NASDAQ:NBIX) five years ago are up 55%
By Yahoo! Finance | 5 months agoNeurocrine Biosciences' stock has risen 55% in five years, below market average, but 39% in the past year. Shareholders have seen improved earnings, indicating potential growth, despite the market's s...